RecruitingPhase 4NCT03933384
Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B
Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B: An Open Label, Randomized Controlled Trial
Sponsor
Taichung Veterans General Hospital
Enrollment
140 participants
Start Date
Aug 19, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.
Eligibility
Min Age: 20 Years
Inclusion Criteria3
- Patients more than 20 years old
- Chronic hepatitis B patients
- Patients who were indicated for hepatitis B virus antiviral therapy
Exclusion Criteria8
- Decompensated liver disease (Child-Pugh B \&C)
- End stage renal disease (eGRF < 15 ml/min/1.73m2)
- Prior use of nucleot(s)ide analogues for chronic hepatitis B
- Prior use of interferon for chronic hepatitis B within six months
- Known history of human immunodeficiency virus or hepatitis C virus co-infection
- Concurrent other uncontrolled malignancy
- Women in pregnancy or lactation
- Cannot conform to the study protocol of this study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGTenofovir alafenamide
Tenofovir alafenamide 25mg/tab once daily
DRUGEntecavir
Entecavir 0.5mg/tab once daily
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03933384
Related Trials
Evaluation of Patients With Liver Disease
NCT000019711 location
Creation of a Cohort for the Quantitation and Characterization of Circulating Viral RNAs as a New Biomarker of Hepatitis B Functional Cure.
NCT038254586 locations
Real World Assessment of People Living With Chronic Hepatitis B in Australia
NCT0491461119 locations
Hep Mec Cohort in Zambia
NCT075899853 locations
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
NCT0712855038 locations